João de Sousa

João de Sousa

Auto-generated profile, based on publicly available information

João de Sousa

Cardiology Department Centro Hospitalar Universitário Lisboa Norte Lisboa Portugal

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 1991 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HCHugh Calkins
Hugh Calkins
JSJoão Sousa
João Sousa
RERafel El-Atassi
Rafel El-Atassi
SRShimon Rosenheck
Shimon Rosenheck
MBMichael de Buitleir
Michael de Buitleir
FMFred Morady
Fred Morady
We conducted this study to determine the feasibility of an abbreviated therapeutic approach to the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardia, in which the diagnosis is established and radiofrequency ablation carried out during a single electrophysiologic test.

8 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EEEmmanuel Ekanem
Emmanuel Ekanem
PNPetr Neuzil
Petr Neuzil
TRTobias Reichlin
Tobias Reichlin
JKJoseph Kautzner
Joseph Kautzner
PVPepijn van der Voort
Pepijn van der Voort
VRVivek Y. Reddy
Vivek Y. Reddy
Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.

1 January 2016 in Circulation Journal
Verified
Journal Article
Open access
PDF file
NCNuno Cortez-Dias
Nuno Cortez-Dias
MCMarina C. Costa
Marina C. Costa
PCPedro Carrilho-Ferreira
Pedro Carrilho-Ferreira
DSDoroteia Silva
Doroteia Silva
CJCláudia Jorge
Cláudia Jorge
Francisco J. EnguitaFrancisco J. Enguita
Francisco J. Enguita
MicroRNAs (miRNAs) are key players in cardiovascular development and disease. However, not only miRNAs of a cardiac origin have a critical role in heart function. Recent studies have demonstrated that miR-122-5p, a hepatic miRNA, increases in the bloodstream during ischemic cardiogenic shock and it is upregulated in the infarcted myocardium. The aim of the present study was to determine the potential of circulating miR-122-5p as a biomarker for early prognostic stratification of ST-segment elevation acute myocardial infarction (STEMI) patients. One hundred and forty-two consecutive STEMI patients treated with primary angioplasty were included in the study. Serum levels of miR-1-3p, -122-5p, -133a-3p, -133b, -208b-3p and -499a-5p were measured at the time of cardiac catheterization by quantitative polymerase chain reaction and related to in-hospital and long-term outcome. During a follow up of 20.8 months, 9 patients died, 6 had recurrence of myocardial infarction, and 26 patients suffered an adverse cardiovascular event. Event-free survival was significantly worse in patients with a higher miR-122-5p/133b ratio (3rd tertile distribution, above 1.42 Log(10)), having almost a 9-fold higher risk of death or myocardial infarction and a 4-fold higher risk of adverse cardiovascular events. This study showed that the miR-122-5p/133b ratio is a new prognostic biomarker for the early identification of STEMI patients at a higher risk of developing major adverse events after undergoing primary percutaneous coronary intervention. (Circ J 2016; 80: 2183-2191).

1 September 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
MCMarina C. Costa
Marina C. Costa
NCNuno Cortez-Dias
Nuno Cortez-Dias
André Filipe Gonçalves GabrielAndré Filipe Gonçalves Gabriel
André Filipe Gonçalves Gabriel
JSJoão de Sousa
João de Sousa
MFManuela Fiúza
Manuela Fiúza
Francisco J. EnguitaFrancisco J. Enguita
Francisco J. Enguita

4 August 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
VLVishal Luther
Vishal Luther
NCNuno Cortez‐Dias
Nuno Cortez‐Dias
LCLuís Carpinteiro
Luís Carpinteiro
JSJoão de Sousa
João de Sousa
RBRichard Balasubramaniam
Richard Balasubramaniam
PKPrapa Kanagaratnam
Prapa Kanagaratnam

1 May 2014 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
NCNuno Cortez‐Dias
Nuno Cortez‐Dias
RPRui Plácido
Rui Plácido
LMLiliana Marta
Liliana Marta
ABAna Bernardes
Ana Bernardes
SSSílvia Sobral
Sílvia Sobral
JSJoão de Sousa
João de Sousa
We present the case of a 60-year-old woman with Brugada syndrome, permanent type 1 electrocardiographic pattern, who had previously received an implantable cardioverter-defibrillator. She suffered frequent syncopal episodes and multiple appropriate shocks (around five per month) due to polymorphic ventricular tachycardia/ventricular fibrillation, refractory to quinidine therapy. Combined epicardial and endocardial electroanatomical mapping was performed with a view to substrate ablation. An area of abnormal fractionated electrograms, lasting up to 370 ms and up to 216 ms after the end of the surface QRS, was identified in the epicardium in the lower anterior part of the right ventricular outflow tract. Extensive epicardial ablation of this area, which eliminated the fractionated electrograms, led to the disappearance of the Brugada electrocardiographic pattern six weeks after ablation. Despite discontinuation of quinidine, no further ventricular arrhythmias occurred during follow-up, which is still of short duration.